Key result
Dobutamine infusion significantly reduced the effective regurgitant orifice area from 0.16 cm2 to 0.09 cm2 in patients with dilated cardiomyopathy and functional mitral regurgitation.
Why the study?
Does dobutamine infusion improve functional mitral regurgitation in relation to LV dyssynchrony and MV geometry in patients with dilated cardiomyopathy?
Observational (n=29)
Does dobutamine infusion improve functional mitral regurgitation in relation to LV dyssynchrony and MV geometry in patients with dilated cardiomyopathy?
In patients with dilated cardiomyopathy, functional mitral regurgitation severity during dobutamine infusion is primarily determined by mitral valve geometry and closing force rather than left ventricular dyssynchrony.
Should not yet change functional MR management; extends evidence prioritizing mitral valve geometry over LV dyssynchrony.
PURPOSE: Functional mitral regurgitation (FMR) and myocardial dyssynchrony commonly occur in patients with dilated cardiomyopathy (DCM). The aim of this study was to elucidate changes in FMR in relation to those in left ventricular (LV) dyssynchrony as well as geometric parameters of the mitral valve (MV) in DCM patients during dobutamine infusion. MATERIALS AND METHODS: Twenty-nine DCM patients (M:F=15:14; age: 62±15 yrs) with FMR underwent echocardiography at baseline and during peak dose (30 or 40 ug/min) of dobutamine infusion. Using 2D echocardiography, LV end-diastolic volume, end-systolic volume (LVESV), ejection fraction (EF), and effective regurgitant orifice area (ERO) were estimated. Dyssynchrony indices (DIs), defined as the standard deviation of time interval-to-peak myocardial systolic contraction of eight LV segments, were measured. Using the multi-planar reconstructive mode from commercially available 3D image analysis software, MV tenting area (MVTa) was measured. All geometrical measurements were corrected (c) by the height of each patient. RESULTS: During dobutamine infusion, EF (28±8% vs. 39±11%, p=0.001) improved along with significant decrease in cLVESV (80.1±35.2 mm³/m vs. 60.4±31.1 mm³/m, p=0.001); cMVTa (1.28±0.48 cm²/m vs. 0.79±0.33 cm²/m, p=0.001) was significantly reduced; and DI (1.31±0.51 vs. 1.58±0.68, p=0.025) showed significant increase. Despite significant deterioration of LV dyssynchrony during dobutamine infusion, ERO (0.16±0.09 cm² vs. 0.09±0.08 cm², p=0.001) significantly improved. On multivariate analysis, ΔcMVTa and ΔEF were found to be the strongest independent determinants of ΔERO (R²=0.443, p=0.001). CONCLUSION: Rather than LV dyssynchrony, MV geometry determined by LV geometry and systolic pressure, which represents the MV closing force, may be the primary determinant of MR severity.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2014) conducted an observational in Dilated cardiomyopathy with functional mitral regurgitation (n=29). Dobutamine infusion vs. Baseline (rest) was evaluated on Effective regurgitant orifice (ERO) area in cm2 (p=0.001). Dobutamine infusion significantly reduced the effective regurgitant orifice area from 0.16 cm2 to 0.09 cm2 in patients with dilated cardiomyopathy and functional mitral regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: